Aqua Bio Technology ASA-logo

Aqua Bio Technology ASA

Følg pressemeldinger fra Aqua Bio Technology ASA

Registrer deg med din e-postadresse for å få de nyeste sakene fra Aqua Bio Technology ASA på e-post fortløpende. Du kan melde deg av når som helst.

Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.

  • Aqua Bio Technology ASA
  • Bygdøy Allé 3
  • 0257 Oslo
Oslo Børs
Vis Alt
År
Vis Alt

Aqua Bio Technology: New share capital registered20.11.2024 12:55:57 CET | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 13 November 2024, regarding the resolution from the general meeting in the Company to increase the share capital in the Company through issuance of 39,363,469 new shares, each with a par value of NOK 2.5, with a subscription price of NOK 3.0 per new share (the "New Shares"). The share capital increase pertaining to the issuance of the New Shares has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). ABT's new share capital is NOK 272,131,855 divided into 108,852,742 shares, each with a nominal value of NOK 2.50. The New Shares will be delivered on a separate ISIN pending publication of an EEA listing prospectus approved by the Norwegian Financial Supervisory Authority. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. About Aqua Bio Technology ASA Aqua Bio Technology (ABT) is developing and comm

1 vedlegg

Divestment from Skinteam Norge AS14.11.2024 13:47:20 CET | Aqua Bio Technology ASA | Innsideinformasjon

Aqua Bio Technology ASA (ABT or the Company) has engaged in a series of acquisitions in recent years. Following an analysis of the development milestones and additional investments required for Skinteam Norge AS (Skinteam) to achieve success, positive cash flow, and synergies for the rest of ABT's companies, ABT has decided to cease further funding for Skinteam. Instead, ABT will focus its liquidity on other group entities expected to generate positive cash flow by 2025. Efforts to transition Skinteam to new ownership have not resulted in a viable solution, and based on recent developments, it is anticipated that Skinteam’s board will now decide or accept to wind down operations. The divestment from Skinteam is projected to result in a significant non-cash impairment charge due to the reduction of goodwill on the Group's balance sheet. However, this decision will improve ABT's liquidity and substantially decrease future capital requirements. Following the completion of the recent Priva

1 vedlegg

Aqua Bio Technology ASA – Primary Insider Notifications13.11.2024 18:44:52 CET | Aqua Bio Technology ASA | Mandatory notification of trade primary insiders

Reference is made to the stock exchange notices from Aqua Bio Technology ASA ("ABT" or the "Company") published on 18 October 2024 regarding the successful placement of new shares (the "New Shares") towards the shareholders of Jetcarrier AS and towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). Reference is also made to the stock exchange announcement by the Company on 17 October 2024, regarding the entry into of a share purchase agreement (the "Agreement") for the purchase of all outstanding shares in Jetcarrier AS, between the Company (as purchaser) and the shareholders of Jetcarrier AS (as sellers) (the "Acquisition"). In the Acquisition, the consideration shares to be delivered to the sellers were resolved issued in connection with the approval of the Private Placement. In an extraordinary general meeting held on 13 November 2024, the share capital increase in connection with the issuance

7 vedlegg

Aqua Bio Technology: Minutes from extraordinary general meeting – Completion of Private Placement and the Jetcarrier Transaction13.11.2024 13:59:25 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA ("ABT" or the "Company") has today held an extraordinary general meeting. All resolutions were made in accordance with the proposals set out in the notice for the extraordinary general meeting which means that the Private Placement and Jetcarrier Transaction announced on 17 October have been completed. The minutes of the extraordinary general meeting are attached to this notice. Following the Jetcarrier Transaction, ABT owns all the shares in Jetcarrier AS which owns 100 % of the shares in Jetcarrier Logistics AS, Isebakkeveien 75 AS, Jetcarrier Solutions AS, Xpanz AS, Norlane AS, Jetcarrier AB, FreightWay AB and Filial Magnoas, and represents a major logistic group in the Nordics. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. About Aqua Bio Technology ASA Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective, and

2 vedlegg

AQUA BIO TECHNOLOGY ASA – SHARE CAPITAL INCREASE REGISTERED12.11.2024 11:46:38 CET | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 29 August 2024, regarding the Company's board of directors' resolution to issue a total of 5,000,000 new shares (the "New Shares") in connection with the settlement of the share component of the purchase price for ABT's acquisition of 3D Innovation Nordic AS. The share capital increase pertaining to the issuance of the New Shares has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). ABT's new share capital is NOK 173,723,182.50 divided into 69,489,273 shares, each with a nominal value of NOK 2.50. The New Shares will be delivered on a separate ISIN pending publication of an EEA listing prospectus approved by the Norwegian Financial Supervisory Authority. For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76. This information is subject of the disclosure requirements pursuant to section 5-12 of the N

1 vedlegg

Aqua Bio Technology: Update on resolutions for general meeting – Cancellation of Subsequent Offering11.11.2024 23:31:20 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the notice for an extraordinary general meeting in Aqua Bio Technology ASA (the "Company") published on 23 October 2024, and to the private placement of new shares in the Company (the "Private Placement") that was announced placed on 18 October, and to the contemplated subsequent offering of new shares following the Private Placement (the "Subsequent Offering"). The Company's auditor has prepared an independent expert report in connection with the Private Placement, which is attached to this stock exchange notice, and forms part of the decision material for the general meeting. In connection with the Private Placement, the Board has also amended its proposal with respect to the Private Placement where the share capital shall be increased with NOK 98,408,672.50 through issuance of 39,363,469 new shares, i.e. one share less than stated in the notice for the extraordinary general meeting. The reason for the amended proposal is an updated counting of certain receivable

2 vedlegg

Aqua Bio Technology: Notice of extraordinary general meeting - Update on consideration to Jetcarrier sellers23.10.2024 16:59:29 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

An extraordinary general meeting of Aqua Bio Technology ASA (the "Company" or "ABT") will be held on 13 November 2024 at 10:00 (CET) at Advokatfirmaet CLP DA, Sommerrogata 13-15, 0255 Oslo. Please find attached the notice to the general meeting. All documents to be treated at the general meeting will be made available at the Company's website www.aquabiotechnology.com - http://www.aquabiotechnology.com. Shareholders who wish to the attend the general meeting is requested to notify the Company as set out in appendix 1 to the notice within 11 November 2024 at 16:00 (CET). In case of attendance by proxy, the proxy form (also included in appendix 1 to the notice) is requested submitted to be received by the Company within the same date. Update on consideration to Jetcarrier sellers As announced on 17 October 2024, the Company has entered into a share purchase agreement with the shareholders of Jetcarrier AS to acquire all outstanding shares in Jetcarrier AS (the "Acquisition"). Further, as

2 vedlegg

Aqua Bio Technology ASA: New CEO appointed22.10.2024 10:15:05 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Oslo, 22 October 2024: Aqua Bio Technology ASA (“ABTEC” or “the Company") is pleased to announce that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. "Håvard Lindstrøm started as CEO in 2021, when ABTEC had less than NOK 2m in revenues. The Board would like to thank Håvard for leading the expansion strategy of ABTEC over the last 3 years and growing the business from 2 small entities to 16 subsidiaries today with a consolidated revenue stream of more than NOK 500m. At the same time, we are very pleased to announce that Fredrik Henriksen has accepted to sign on as our new CEO as the ABT Group is entering a new commercial phase to utilize market potential both in B2B and B2C/D2C channels and value chain optimalization, after a period of acquisitions and impressive expansion" says Jon Olav Ødegård, Chair of the Board of Aqua Bio

1 vedlegg

Correction: Aqua Bio Technology ASA – Private Placement successfully placed18.10.2024 09:38:53 CEST | Aqua Bio Technology ASA | Inside information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Correction: The total number of New Shares to be issued was incorrect. Please see updated version below. Reference is made to the stock exchange notice from Aqua Bio Technology ASA ("ABT" or the "Company") published on 17 October 2024 regarding a contemplated conditional private placement of 19 million new shares towards the shareholders of Jetcarrier AS and minimum 18.33 million and maximum 22 million new shares (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). Reference is also made to the stock exchange a

1 vedlegg

Aqua Bio Technology ASA – Private Placement successfully placed18.10.2024 08:54:34 CEST | Aqua Bio Technology ASA | Inside information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from Aqua Bio Technology ASA ("ABT" or the "Company") published on 17 October 2024 regarding a contemplated conditional private placement of 19 million new shares towards the shareholders of Jetcarrier AS and minimum 18.33 million and maximum 22 million new shares (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). Reference is also made to the stock exchange announcement by the Company on 17 October 2024, regarding the entry into of a share purchase agreement for

1 vedlegg

Aqua Bio Technology ASA – Key information relating to the Subsequent Offering18.10.2024 08:53:02 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the announcement by Aqua Bio Technology ASA on 18 October 2024 concerning the successful placement of the conditional private placement with total gross proceeds of approximately NOK 115 million, and a contemplated subsequent offering (the "Subsequent Offering"). Key information for the Subsequent Offering is set out below: Date on which the terms of the Subsequent 17 October 2024 Offering was announced: Last day including right: 17 October 2024 First day excluding right: 18 October 2024 Record date: 21 October 2024 EGM date: On or about 12 November 2024 (to be summoned) Maximum number of new shares: 2,000,000 Subscription price: NOK 3.00 Shall the rights be listed No The issuance of new shares in the Subsequent Offering will be subject to approval of the pertaining share capital increase by the EGM to be held on or about 12 November 2024. The Subsequent Offering is expected to be carried out during the notice period for the EGM, with a one-week subscription period

1 vedlegg

Aqua Bio Technology ASA – Contemplated Private Placement17.10.2024 17:48:42 CEST | Aqua Bio Technology ASA | Inside information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Aqua Bio Technology ASA ("ABT" or the "Company") hereby announces a contemplated conditional private placement of 19 million new shares towards the shareholders of Jetcarrier AS and minimum 18.33 million and maximum 22 million new shares (together, the "New Shares") towards certain new investors and certain existing shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private Placement"). The Company further contemplates to carry out a subsequent offering towards eligible shareholders. Reference is also made to the stock exchange announcement by the Company earlier today, 17 October 2024, regarding the entry i

1 vedlegg

Aqua Bio Technology ASA – Inngått avtale om oppkjøp av Jetcarrier AS17.10.2024 17:38:09 CEST | Aqua Bio Technology ASA | Innsideinformasjon

Det vises til børsmelding fra Aqua Bio Technology ASA ("ABT" eller "Selskapet", og sammen med sine konsoliderte datterselskap, "ABT-Konsernet") den 12. juni 2024 vedrørende inngåelse av en prinsippavtale for oppkjøp av Jetcarrier AS ("Jetcarrier", og sammen med sine datterselskaper, "Jetcarrier-konsernet"). Selskapet har i dag inngått endelig aksjekjøpsavtale ("Avtalen") med aksjonærene i Jetcarrier for oppkjøpet av samtlige aksjer i Jetcarrier ("Oppkjøpet"). Jetcarrier-konsernet er et logistikk og fraktselskap med stort fokus på teknologisk utvikling. De håndterer millioner av pakker for B2B- og B2C-markedet hvert år og har hatt en jevn vekst siden oppstarten i 2000. Driftsinntektene i 2023 var nær 350 MNOK med en EBITDA på 13 MNOK. Jetcarrier-gruppens ureviderte inntekter for første halvår 2024 var nær 169 MNOK, en vekst på over 20% sammenlignet med samme tid i fjor. For 2024 forventer Jetcarrier-gruppen å generere inntekter på minst 370 MNOK. Vekst og synergier Gjennom oppkjøpet av

2 vedlegg

AQUA BIO TECHNOLOGY ASA – ISSUANCE OF CONSIDERATION SHARES AND DISCLOSURE OF LARGE SHAREHOLDING29.8.2024 15:09:52 CEST | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to the stock exchange notice from Aqua Bio Technology ASA (the "Company" or "ABT") on 28 August 2024 regarding the completion of the Company's acquisition of 100 % of the shares in 3D Innovation Nordic AS pursuant to a share purchase agreement (the "SPA") entered between the Company as buyer and CoC Invest AS ("CoC Invest") as seller, a company with Ørjan Djuvik Pedersen, Jesper Dønnestad Brandt and Rolf Kristian Fiala as ultimate owners. To settle the share component of the purchase price under the SPA, the Company's board of directors has today resolved to issue 5,000,000 consideration shares at a subscription price of NOK 3,66 per consideration share, each with a nominal value of NOK 2,50 (the "Consideration Shares"), pursuant to a board authorization registered in the Norwegian Register of Business Enterprises on 5 July 2024. The Consideration Shares are subject to a 36-month lock up undertaking and will be delivered on a separate ISIN pending the Company's public

1 vedlegg

Aqua Bio Technology ASA: Acquisition of the 3D Innovation Nordic AS group completed28.8.2024 22:45:28 CEST | Aqua Bio Technology ASA | Inside information

Reference is made to the stock exchange announcement made by Aqua Bio Technology ("ABT" or the "Company", and together with its wholly owned subsidiaries, the "ABT Group") on 25 April 2024 regarding the Company's entry to an agreement in principle to acquire all of the outstanding shares in 3D Innovation Nordic AS ("3D Innovation") (the "Transaction"). 3D Innovation with its subsidiaries represent a major wholesale group in the Nordics (the "Target Group"). The Transaction has today been completed making ABT the 100 % direct and indirect owner of the Target Group. For the first half of 2024, the Target Group had an unaudited turnover of NOK 40 million with an EBITDA of NOK 3 million. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5,000,000 new shares at subscription price of NOK 3,66 per share, equal to today's opening trading price of the Company's shares, with a 3

1 vedlegg

Aqua Bio Technology ASA - Results for first half year 202423.8.2024 22:30:48 CEST | Aqua Bio Technology ASA | Half yearly financial reports and audit reports / limited reviews

Agreement in principle to acquire Jetcarrier AS, a major international warehouse and logistic group. Agreement in principle acquisition of 3D Innovation Nordic AS and affiliated companies, together a potential major wholesale group in the Nordics. Cosmed Beauty AS buyout and named new CFO for the ABT group Jan Varming. Entered into agreement for the acquisition of Ovalen AS (Pusterom Hudpleie) and completed the acquisition. Private placement sucessfully placed. Due to the Group's increased activity ABT started with quarterly reports to the market. The company's revenues in the first half of 2024 were NOK 61.1 million versus NOK 7.2 million in the same period last year. Cost of goods amounted to NOK 35.4 million in the first half of the year, compared with NOK 3.2 million in the same period last year. The company's salary costs and other sales and administration costs (excluding cost of goods) were NOK 31.8 million in the first half of 2024. In the same period last year, the costs were

2 vedlegg

AQUA BIO TECHNOLOGY ASA – SHARE CAPITAL INCREASE REGISTERED4.7.2024 10:08:04 CEST | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 28 June 2024, regarding the Company's board of directors' resolution to issue a total of 5,908,935 new shares (the "New Shares") in connection with the settlement of the purchase price for ABT's acquisition of Ovalen AS and the buy-out of Varming Holding AS related to the Company's acquisition of Cosmed Beauty AS and Ultrabody AB. The New Shares will be delivered on a separate ISIN pending publication of an EEA listing prospectus approved by the Norwegian Financial Supervisory Authority. The share capital increase pertaining to the issuance of the New Shares has today been registered with the Norwegian Registry of Business Enterprises (Nw. Foretaksregisteret). ABT's new share capital is NOK 161,223,182.50 divided into 64,489,273 shares, each with a nominal value of NOK 2,50. For further information, please contact Håvard Lindstrøm, CEO, telephone +47 941 32 288. * Aqua Bio Tech

1 vedlegg

Framework agreement for the strategic use of AI2.7.2024 13:12:01 CEST | Aqua Bio Technology ASA | Non-regulatory press releases

Aqua Bio Technology ASA (ABT) and SeeyouAI have entered into a strategic framework agreement on using artificial intelligence (AI) for ABT's existing and future portfolio companies. ABT and SeeyouAI have entered into a framework agreement for AI solutions for ABT's portfolio companies. The goal is to save resources and enable previously impossible services by improving customer service, employee support, purchasing optimization, inventory management, and market intelligence. About seeyouAI SeeyouAI has, over the past four years, spent over 300,000 development hours developing seeyouGPT, the core of a set of European GDPR-compliant AI assistants for the corporate and private markets. The company has a wide range of Norway's most reputable investors on the ownership side, and the technology has been pre-tested in over 100 countries. See the links below for press release and note for seeyouGPT's open beta launch for consumers. - Norwegian Press release SeeyouGPT: https://kommunikasjon.ntb

1 vedlegg

Aqua Bio Technology ASA: Cosmed and Ovalen AS settlement28.6.2024 14:46:59 CEST | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to the stock exchange announcements made by Aqua Bio Technology ASA ("ABT" or the "Company") on 12 April and 23 April 2024, respectively, regarding the completion of ABT's acquisition of Ovalen AS and the settlement of the earn-out in relation to the Company's acquisition of Cosmed Beauty AS and Ultrabody AB (jointly, "Cosmed"). The Company's board of directors has resolved to issue 1,200,000 consideration shares at a subscription price of NOK 5 per consideration share to the previous owner of Ovalen AS. Moreover, for accounting purposes, the buy-out owed to Varming Holding AS in connection with the Company's acquisition of Cosmed has been rescinded, and the settlement of the buy-out has been agreed to be amended. On this basis, the Company's board of directors has resolved to issue 4,707,935 shares at a subscription price of NOK 4 to Varming Holding AS, with the share deposit being settled by way of set-off. **** For further information, please contact CEO Håvard Lin

1 vedlegg
  • 1
  • 2
  • 3
  • 4
  • 5
  • Siste
  • >>

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.

  • Aqua Bio Technology ASA
  • Bygdøy Allé 3
  • 0257 Oslo
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye